Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its position in Accelerate Diagnostics Inc (NASDAQ:AXDX) by 6.2% during the 1st quarter, HoldingsChannel reports. The fund owned 14,392 shares of the medical research company’s stock after buying an additional 836 shares during the quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Accelerate Diagnostics were worth $303,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently modified their holdings of the company. Vanguard Group Inc boosted its holdings in shares of Accelerate Diagnostics by 0.8% in the third quarter. Vanguard Group Inc now owns 1,291,417 shares of the medical research company’s stock valued at $29,638,000 after acquiring an additional 10,601 shares in the last quarter. Man Group plc purchased a new stake in shares of Accelerate Diagnostics in the third quarter valued at about $313,000. BlackRock Inc. boosted its holdings in shares of Accelerate Diagnostics by 2.0% in the third quarter. BlackRock Inc. now owns 1,785,849 shares of the medical research company’s stock valued at $40,983,000 after acquiring an additional 34,958 shares in the last quarter. FMR LLC boosted its holdings in shares of Accelerate Diagnostics by 25.1% in the fourth quarter. FMR LLC now owns 738,449 shares of the medical research company’s stock valued at $8,492,000 after acquiring an additional 148,099 shares in the last quarter. Finally, Stifel Financial Corp boosted its holdings in shares of Accelerate Diagnostics by 24.6% in the fourth quarter. Stifel Financial Corp now owns 556,763 shares of the medical research company’s stock valued at $6,365,000 after acquiring an additional 110,034 shares in the last quarter. 48.90% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts recently commented on AXDX shares. Zacks Investment Research downgraded shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Wednesday, April 10th. ValuEngine raised shares of Accelerate Diagnostics from a “hold” rating to a “buy” rating in a report on Friday. Finally, BidaskClub raised shares of Accelerate Diagnostics from a “hold” rating to a “buy” rating in a report on Wednesday, March 27th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $18.75.
AXDX stock opened at $20.63 on Friday. Accelerate Diagnostics Inc has a 52 week low of $10.23 and a 52 week high of $24.75. The company has a debt-to-equity ratio of 2.09, a current ratio of 22.88 and a quick ratio of 21.89.
Accelerate Diagnostics (NASDAQ:AXDX) last released its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.03. The firm had revenue of $1.75 million for the quarter, compared to the consensus estimate of $2.12 million. Accelerate Diagnostics had a negative net margin of 1,352.80% and a negative return on equity of 116.58%. On average, analysts expect that Accelerate Diagnostics Inc will post -1.79 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was first published by Macon Daily and is the property of of Macon Daily. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://macondaily.com/2019/05/11/mitsubishi-ufj-kokusai-asset-management-co-ltd-has-303000-stake-in-accelerate-diagnostics-inc-axdx.html.
Accelerate Diagnostics Profile
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.
See Also: Why do companies pay special dividends?
Want to see what other hedge funds are holding AXDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accelerate Diagnostics Inc (NASDAQ:AXDX).
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.